Today: 21 May 2026
Johnson & Johnson stock price slips after hours as healthcare lags — what’s next for JNJ
10 February 2026
1 min read

Johnson & Johnson stock price slips after hours as healthcare lags — what’s next for JNJ

New York, Feb 9, 2026, 19:11 EST — Trading in the after-hours session.

Shares of Johnson & Johnson (JNJ) slipped 0.6% to $238.64 in after-hours action Monday, as traders pulled back from healthcare stocks. The stock swung from $237.04 up to $240.74 over the session. Volume hit around 9.4 million shares.

The broader market stayed resilient, with SPDR S&P 500 ETF Trust (SPY) up 0.5%. The Invesco QQQ Trust (QQQ) did a bit better, adding 0.8%. Health care stocks struggled; the sector’s ETF, XLV, slipped 0.9%.

Johnson & Johnson is slated for a slot at the Barclays 28th Annual Global Healthcare Conference on March 10, where management will take questions in an 11:30 a.m. Eastern fireside chat. Investors can catch a live webcast through the company’s investor relations portal, and a replay should land roughly 48 hours after the event.

Merck tumbled 3.5%, dragging other major drugmakers lower. Pfizer edged down 0.7%, while Eli Lilly shed 1.3%.

J&J’s latest conference appearance follows January’s earnings report, which showed fourth-quarter sales reaching $24.6 billion and adjusted earnings at $2.46 a share. The company is targeting sales between $100.0 billion and $101.0 billion for 2026, with adjusted EPS guided to a range of $11.43 to $11.63. CEO Joaquin Duato described 2025 as “a catapult year.” SEC

With thinner volumes after hours, even modest sentiment changes can move prices more than usual. Many traders, though, hold off until the market opens again to find out if those initial swings hold up.

Litigation still looms large. Johnson & Johnson faces over 67,500 lawsuits tied to its talc-based baby powder, maintaining the products are safe and cancer-free. Last week, a New Jersey appeals court kicked one plaintiffs’ firm off the state cases for an ethics violation—a move the firm plans to fight.

There’s another date to watch: Johnson & Johnson’s board has locked in a $1.30 per share quarterly dividend, due out March 10. The ex-dividend date lands on Feb. 24, stripping new buyers of the next payment, according to the company.

Stock Market Today

  • Analysts Boost Broadcom Price Targets Despite Stock Dip
    May 20, 2026, 11:22 PM EDT. Broadcom (AVGO) shares fell 6.5% to $411.07 on May 19, retreating from a record high of $439.79 on May 14. Despite this drop, several major analysts raised their price targets. Wells Fargo lifted its target to $545 from $430, TD Cowen to $500 from $405, and UBS to $490 from $475, all maintaining buy ratings. Evercore ISI's Mark Lipacis, a top-ranked analyst, raised his target to $582, citing growing demand for Broadcom's custom AI chips amid shifts in AI workloads. Risks remain from semiconductor market volatility and geopolitical tensions impacting chip deals. Broadcom's strategic moves, including its VMware acquisition and partnerships with Google and Meta for AI-focused chips, position it well in enterprise infrastructure and AI growth.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
AI stocks brace for a big week: Micron slips on Samsung HBM4 talk as Nvidia looms
Previous Story

AI stocks brace for a big week: Micron slips on Samsung HBM4 talk as Nvidia looms

India fintech MIDASX hits best quarter, turns cash-flow positive as it scales AI-led distribution
Next Story

India fintech MIDASX hits best quarter, turns cash-flow positive as it scales AI-led distribution

Go toTop